ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2829

Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality

Nigil Haroon1, Nisha Nigil Haroon2, Ping Li3, Michael Paterson3 and Robert D. Inman4, 1Toronto Western Research Institute, Toronto, ON, Canada, 2Medicine, University of Toronto, Toronto, ON, Canada, 3Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, 4Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Cardiovascular disease, Epidemiologic methods, population studies and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be at increased risk of cardiovascular disease but it is unknown if they have excess vascular mortality. We explored risk of vascular mortality and the contributing factors in AS.

Methods

We performed a population-based, retrospective cohort study on incident SpA patients, age 15 or above, living in Ontario, Canada between April 1995 and March 2011. There were 21,878 SpA cases and 87,504 controls (matched for age, gender and socioeconomic status). The primary outcome was a composite event of cardiovascular or cerebrovascular deaths coded as the primary cause on death certificates. Considering the large size of the cohorts, we used standardized differences to compare the baseline characteristics of those with AS and their matched controls. Cox proportional hazards model was used to estimate differences in vascular mortality between cases and controls. Crude and adjusted hazard ratios (HR) were calculated and adjustments were made for coronary and cerebrovascular disease (CAD, CVD), cancer, diabetes, dementia, inflammatory bowel disease, hypertension, chronic kidney disease (CKD) and peripheral vascular disease (PVD). Additionally, we used a separate model in those with AS to identify covariates associated with vascular mortality. Finally, we constructed survival curves using the Kaplan-Meier (KM) method and tested for survival differences among groups using the Log-Rank test.

Results

In the SpA cohort 53% were male, with a mean age of 46 ±16 years, and a follow-up of 169,307 patient-years. Follow-up for controls was 692,499 patient-years. Crude and adjusted HR (95%CI) for vascular deaths were 1.49 (1.26-1.77) and 1.36 (1.14-1.63) respectively, indicating a 36-49% higher risk of vascular mortality in AS. Crude HR (95%CI) in males and females were 1.63 (1.31-2.03) and 1.31(1.00-1.71) respectively. Cases and controls had similar prevalence of CAD, CVD, PVD, dementia and diabetes, but IBD (6% vs 4%), hypertension (24% vs 18%) and CKD (2% vs 0.8%) were more common in SpA. The predictors of vascular death were age, male sex, low income, CKD and PVD apart from CAD and CVD.  The KM curve showing an increase in vascular mortality in AS patients is shown in figure 1.

Conclusion

This is the first population-based study to demonstrate SpA is associated with significantly risk of vascular mortality. These new findings should prompt a comprehensive strategy to screen and treat modifiable vascular risk factors in SpA patients.

 

Figure 1. Kaplan-Meier Survival Curve of AS patients compared to non-AS controls after correcting for baseline variables


Disclosure:

N. Haroon,
None;

N. Nigil Haroon,
None;

P. Li,
None;

M. Paterson,
None;

R. D. Inman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spondyloarthritis-is-associated-with-increased-cardiovascular-and-cerebrovascular-mortality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology